CANPAIN Feasibility Study Pragmatic Real World Trial Investigating CBMP in Chronic Pain Patients (CANPAIN)
CANPAIN Feasibility Study: Evaluating the Feasibility of Subsequently Undertaking a Pragmatic Real World Trial Investigating CBMP in Chronic Pain Patients
The CANPAIN study has been devised to evaluate the efficacy and safety of a defined cannabis based medicinal product (CBMP) delivered by inhalation to patients with non cancer chronic pain attending a private clinic. CANPAIN is a pragmatic non-randomised, non-blinded real-world trial of the safety, tolerability and effectiveness of a cannabis based medicinal product (CBMP) for the treatment of chronic non-cancer pain compared against matched controls receiving standard of care pain management. CANPAIN will run for 3 years with a minimal planned sample size of 5000 participants per group who have completed at least 12 months of treatment. CANPAIN will be an MHRA and REC approved study. (See Appendix 1 of the Feasibility Study for the full draft protocol of the CANPAIN Study)
Prior to commencing the CANPAIN study, the sponsor proposes to conduct a feasibility study. This study will aid in establishing likely rates of patient recruitment, duration of participant enrolment in the study, the demographic and geographic spread of patients, patient acceptability of data collection and identify any issues with technological and drug delivery logistics.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The feasibility study will be based within a private clinic setting and will only involve existing patients of the clinic. The treatment regime, tests that the patients are required to take, the clinical information they are required to provide, and the informed consent required for treatment, will all follow the clinical protocol. The sponsor wishes to assess the feasibility of conducting the study within the private clinic to aid a future submission to Oxford A REC of the CANPAIN study.
The feasibility study will be conducted over a 3-month period with a minimum target recruitment number of 100 patients. Feasibility will be assessed through 3 distinct domains: Recruitment and patient experience, medication logistics and data management.
Patient experiences (part of domain 3) will be captured using comment forms, requesting feedback on ease of onboarding, ease of answering questionnaires, evidence of questionnaire fatigue and their satisfaction of service.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W1G 9HH
- LVL Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A consented patient at the clinic;
- Male or female 18-85 years old;
- Diagnosed with chronic non-cancer pain;
- Is currently receiving standard of care but still has pain, has completed standard of care pain treatment, does not want standard of care treatment, or standard of care is contraindicated. An inadequate response is defined as the subject receiving standard analgesic agents and still has pain, has unpleasant side effects or wishes to reduce their intake of standard of care analgesic agents, e.g. a subject receiving opioids who wishes to dose reduce in light of the "opioid crisis";
- Despite being on or having received standard of care and has still pain (>3 on the Pain NRS); and
- Signed and dated consent form from the patient.
Exclusion Criteria:
- Pregnant or lactating females or females who are planning a pregnancy during the study;
- Positive pregnancy test at time of joining the clinic;
- Major organ failure, renal, lung or liver failure;
- Participants having active liver disease or unexplained persistent elevation of serum transaminases > 3 times the upper limit of normal;
- Participants with a creatinine clearance < 60mL/min;
- History of cardiac or respiratory failure;
- History of recent myocardial infarction or poorly controlled ischaemic heart disease;
- Severe respiratory disease (e.g., GOLD 3 for COPD or asthmatics requiring high doses of oral corticosteroids);
- History or presence of alcohol or substance abuse, including analgesics used as standard of care;
- Participation in a clinical trial of an investigational medicinal product;
- With any known or suspected history or family history of schizophrenia, or other psychotic illness; history of severe personality disorder or other significant psychiatric disorder disorders other than depression associated with their underlying condition;
- Known hypersensitivity to cannabis or allergy to cannabis or CBMP; and
- Currently taking cannabis and does not agree to a 3 week wash out period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Active Group
Patients of the clinic receiving cannabis treatment for non cancer chronic pain, who have been invited to join the study and have agreed and consented to join study.
|
The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Experience
Time Frame: 3 months
|
Assess rate of recruitment to the clinic.
Measure time taken to recruit the first 100 patients from time of first patient in study until end of study.
This will be measured using an electronic patient record which will record the date each patient entered and left the study.
|
3 months
|
|
Duration of Time in Study
Time Frame: 3 months
|
Assess the number/proportion of patients that cease treatment at the Clinic.
Measure the average time all patients remained in the study.
This will be measured using an electronic patient record which will record the date each patient entered and left the study.
|
3 months
|
|
Questionnaire Compliance
Time Frame: 3 months
|
Assess the number of patients that complete all questionnaires required.
Measure the percentage of patients that completed all questionnaires required as part of the study.
|
3 months
|
|
Safety Questionnaire Results
Time Frame: 3 months
|
Assess the number of patients that experience safety issues.
Report the number of patients that recorded a score of 5 or more on the NRS tolerability questionnaire, in any of the safety questions.
|
3 months
|
|
Medication Logistics
Time Frame: 3 months
|
Assess the timeliness and efficiency of CBMP delivery to the patient.
Record average time taken for medication to reach patients after prescription has been completed using the shipping data from the pharmacy and the receipt date by the patient from the courier.
|
3 months
|
|
Device Experience
Time Frame: 3 months
|
Assess the presence of issues with the usability of the inhalation device.
Record number of patients that had issues with using the device from the comments questionnaire and from emails and phone calls to the study site.
|
3 months
|
|
Onboarding Experience
Time Frame: 3 months
|
Ease of onboarding.
Report from comments questionnaire and email and phone interactions with study site number of patients that had difficulties with registering with the clinic and entering into the study.
|
3 months
|
|
Questionnaire Logistics and Satisfaction
Time Frame: 3 months
|
Ease of answering questionnaires.
Record the number of patients that had problems with accessing or filling in the questionnaires from comments questionnaire and email and phone interactions with the study site.
|
3 months
|
|
Questionnaire Fatigue
Time Frame: 3 months
|
Evidence of questionnaire fatigue.
Report on the number of people that did not complete all questionnaires or did not complete them correctly or who complained about the number of questionnaires and questions in each questionnaire from the comments form and emails and phone calls to study site.
|
3 months
|
|
Patient Satisfaction with Service
Time Frame: 3 months
|
Patients are required to fill out a Feedback Questionnaire which has a number of questions within it regards the service provided.
Patients are required to rate the answers to these questions as Excellent, Good, Fair or Poor.
The percentage of patients recording Excellent, Good, Fair and Poor will be calculated and tabulated and reported on.
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demographic
Time Frame: 3 months
|
Assess the socio-economic status and geographic origin of patients.
Report on the number of patients by postcode to get an impression of socio-economic and demographic spread of the patients.
|
3 months
|
|
Conversion to Registration
Time Frame: 3 months
|
Assess the number of enquiries to webpage and completion of registration forms.
Report on the number of visits to the study site website and what percentage of these lead to a registration form being completed by the patient.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shaw Sorooshian, MB ChB, LVL Health
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRAS 304548
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
NCT06638437Not yet recruitingChronic Post-operative Pain | Chronic Postsurgical Pain | Chronic Post-surgical Pain | Chronic Postoperative Pain
-
NCT03119896CompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain Hip
-
NCT07081737Not yet recruitingPain Management | Pain, Chronic | Chronic Pain, Widespread
-
NCT06906211RecruitingChronic Back Pain | Chronic Pain (back / Neck)
-
NCT07179016RecruitingJoint Pain | Chronic Knee Pain | Chronic Pain (Back / Neck) | Chronic Pain Management
-
NCT06759675Not yet recruiting
-
NCT01967342CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to Injury
-
NCT03249558CompletedChronic Low Back Pain | Chronic Neck Pain
-
NCT05616702RecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back Pain
-
NCT07010627Enrolling by invitationChronic Low Back Pain | Chronic Shoulder Pain | Chronic Knee Pain
Clinical Trials on Cannabis
-
NCT04982965RecruitingLower Back Pain | Back Pain | Sciatica | Degenerative Disc Disease | Lumbar Radiculopathy | Chronic Low-back Pain (cLBP) | Chronic Low Back and Leg Pain
-
NCT04841993CompletedHealthy Subjects | Cannabis Use
-
NCT04596644SuspendedPain | Cannabis | Hyperalgesia | Tolerance
-
NCT04576507CompletedPain | Cannabis | Hyperalgesia | Tolerance
-
NCT02177513Completed
-
NCT06190470Enrolling by invitation
-
NCT07224698Not yet recruitingPost Traumatic Stress Disorder PTSD
-
NCT06059677RecruitingDriving Impaired | Cannabis Smoking